Medulloblastoma: presentation, diagnosis and management

Area of Science:

• Pediatric Oncology
• Neuro-oncology
• Central Nervous System Malignancies

Background:

• Primitive neuroectodermal tumor or medulloblastoma (PNET/MB) is the most frequent malignant brain tumor in children.
• Historically, PNET/MB had a uniformly fatal prognosis, but recent therapeutic advances have improved outcomes.
• Significant gaps remain in understanding childhood central nervous system malignancies.

Purpose of the Study:

• To review the current management strategies for pediatric PNET/MB.
• To highlight advances in treatment and identify areas for future research.
• To discuss the prognostic stratification and long-term sequelae of PNET/MB treatment.

Main Methods:

• Review of recent advancements in the surgical, radiotherapeutic, and chemotherapeutic management of PNET/MB.
• Analysis of prognostic subgroup stratification based on detailed postoperative evaluation.
• Examination of the impact of multimodal therapy on survival rates and treatment-related sequelae.

Main Results:

• Aggressive surgery and radiotherapy achieve a 5-year survival rate exceeding 50% for pediatric PNET/MB.
• Postoperative evaluation allows stratification into average and poor prognosis subgroups.
• Addition of chemotherapy to radiotherapy significantly improves survival for high-risk patients.
• Current treatments are associated with significant endocrinological and intellectual sequelae.

Conclusions:

• Multimodal therapy has transformed PNET/MB from a uniformly fatal disease to one with a >50% 5-year survival rate.
• Prognostic stratification and risk-adapted therapy are crucial for optimizing PNET/MB management.
• Addressing the long-term endocrinological and intellectual sequelae of treatment is essential for improving the quality of life for survivors.